drugset / Trial / NCT03956355

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

NCT03956355

Phase 3 Completed 510 enrolled Organon and Co IQVIA Biotech · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.

Timeline

Start
2019-05-21
Primary completion
2020-05-26
Completion
2020-05-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tapinarof Other / unclassified 1 % Topical

Indications